SLC8A1 and amyotrophic lateral sclerosis: As demostrated by Anzilotti et al. (2018) another pharmacological target to be considered as putative approach to slow down ALS progression is NCX3, an isoform of the plasmamembrane protein Na+/Ca2+ exchanger.